Abstract
Proteomics applications to study the molecular effects of drug administration (pharmacoproteomics) on left ventricular hypertrophy (LVH) and atherosclerosis are here reviewed. In most cases, an absence of complete normalization after treatment is revealed, in contrast to what is reported by classical approaches.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antihypertensive Agents / therapeutic use
-
Atherosclerosis / drug therapy*
-
Atherosclerosis / metabolism*
-
Calcium Channel Blockers / therapeutic use
-
Dose-Response Relationship, Drug
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hypertrophy, Left Ventricular / drug therapy*
-
Hypertrophy, Left Ventricular / metabolism*
-
Myocardium / metabolism
-
Proteome / metabolism*
-
Proteomics
Substances
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Proteome